Superbug-busting drugs will be rolled out on the NHS to help stop routine operations becoming fatal within a decade.
A world-first subscription deal will pay pharma firms to keep drugs in reserve to tackle the most serious infections that have become resistant to antibiotics.
NHS England announced around 1,700 patients per year with severe bacterial infections will be eligible for the drugs, called ceftazidime–avibactam and cefiderocol, manufactured by Pfizer and Shionogi.
